Get the Stockscreener App
568.43
0.45%
2.56
United Therapeutics Corp stock is traded at $568.43, with a volume of 265.29K.
It is up +0.45% in the last 24 hours and down -1.02% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$565.87
Open:
$567.3
24h Volume:
265.29K
Relative Volume:
0.51
Market Cap:
$24.13B
Revenue:
$3.17B
Net Income/Loss:
$1.29B
P/E Ratio:
20.98
EPS:
27.0947
Net Cash Flow:
$1.01B
1W Performance:
-0.03%
1M Performance:
-1.02%
6M Performance:
+19.71%
1Y Performance:
+84.12%
1-Day Range:
$563.04
$570.64
1-Week Range:
$555.25
$578.60
52-Week Range:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares - Investing.com India
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares By Investing.com - Investing.com South Africa
United Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com
United Therapeutics CEO Rothblatt sells $5.4m in common stock - Investing.com
United Therapeutics CEO Rothblatt sells $5.4m in common stock By Investing.com - Investing.com UK
UTHR Technical Analysis | Trend, Signals & Chart Patterns | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
United Therapeutics (UTHR) Remains a Key Holding for Renaissance Technologies - GuruFocus
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock - Investing.com Nigeria
United Therapeutics (UTHR) Reports TETON Study Results on Nebuli - GuruFocus
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock By Investing.com - Investing.com South Africa
United Therapeutics’ Tyvaso meets primary endpoint in IPF trial - Investing.com
Inhaled Tyvaso preserves lung function, cuts IPF risks in trial - Stock Titan
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics (UTHR) Reports Positive Ralinepag Results in Pulmonary Hypertension Study - GuruFocus
Baidu, Brady And 3 Stocks To Watch Heading Into Monday - Benzinga
Experimental PAH pill ralinepag cuts worsening risk 55% in Phase 3 - Stock Titan
Leuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock (US9113631090): FDA clears first UHeart xenotransplantation trial - AD HOC NEWS
United Therapeutics Corporation $UTHR Stock Position Decreased by Thrivent Financial for Lutherans - MarketBeat
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call - Yahoo Finance
United Therapeutics Corporation Announces Fda Clearance to Proceed with Uheart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics stock (US9113631090): fresh data push at ATS 2026 keeps pipeline in focus - AD HOC NEWS
United Therapeutics (UTHR) Receives FDA Approval for UHeart Clin - GuruFocus
FDA clears first human trial of pig-derived transplant heart - Stock Titan
United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares - MarketBeat
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
Varda Space and United Therapeutics to test drugs in space microgravity - Новости GxP
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock By Investing.com - Investing.com Canada
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock - Investing.com
Pacer Advisors Inc. Trims Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Ameritas Advisory Services LLC Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
Varda Space, United Therapeutics to test lung drugs in orbit - qz.com
United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
United Therapeutics director Mesa Nilda sells $150,139 in stock By Investing.com - Investing.com Australia
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics director Mesa Nilda sells $150,139 in stock - Investing.com
Varda Space, United Therapeutics partner on drug development By Investing.com - Investing.com India
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EDGEMOND JAMES | CFO AND TREASURER |
May 21 '26 |
Sale |
564.11 |
10,000 |
5,641,130 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 21 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 21 '26 |
Sale |
564.11 |
9,500 |
5,359,011 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 20 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 20 '26 |
Sale |
565.98 |
9,500 |
5,376,814 |
40,513 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
May 21 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
May 21 '26 |
Sale |
562.82 |
8,300 |
4,671,399 |
45,172 |
1.15%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):